Výsledky vyhledávání

Preferences of Canadian Patients and Physicians for Treatment of HR+/HER2− Advanced Breast Cancer

Autor: Daniel Stellato, M. Thabane, Thomas E. Delea, Caitlin Eichten

Publikováno v: Current Oncology, Vol 28, Iss 51, Pp 491-508 (2021)
Current Oncology
Volume 28
Issue 1
Pages 51-508

(1) Background: Past research suggests that patients with advanced breast cancer prefer treatments with improved clinical outcomes and lower risk of side effects. Evidence on preferences of Canadian patients and physicians for treatments for advanced

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f59aafd7de9a9516133f3c53a0f6305c
https://doi.org/10.3390/curroncol28010051

Zobrazit plný text záznamu

Preferences of Canadian Patients and Physicians for Adjuvant Treatments for Melanoma

Autor: M. Thabane, Thomas E. Delea, Daniel Stellato, Caitlin Eichten

Publikováno v: Current Oncology
Volume 26
Issue 6
Pages 5085-765

Past research suggests that patients with early- and late-stage melanoma will endure adverse events and inconvenient treatment regimens for improved survival. Evidence about the preferences of Canadian patients and physicians for novel adjuvant treat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::82b9ada226e07d3c11034394e8725c55
https://doi.org/10.3747/co.26.5085

Zobrazit plný text záznamu

Cost Effectiveness of Ribociclib Plus a Nonsteroidal Aromatase Inhibitor in Pre-/Perimenopausal, HR+ and HER2- Advanced Breast Cancer: A Canadian Healthcare Perspective

Autor: Jinhee Park, M. Thabane, Thomas E. Delea, Daniel Stellato, David Chandiwana

Publikováno v: PharmacoEconomics. 39(7)

The MONALEESA-7 trial demonstrated the efficacy and safety of ribociclib plus a nonsteroidal aromatase inhibitor (NSAI) [with goserelin] for pre-/perimenopausal women with hormone receptor-positive and human epidermal growth factor receptor 2-negativ

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2cd5c25373d66e27e03911aed6e97fc5
https://pubmed.ncbi.nlm.nih.gov/34002341

Zobrazit plný text záznamu

Cost Effectiveness of Ribociclib in Combination with Fulvestrant for the Treatment of Postmenopausal Women with HR+/HER2- Advanced Breast Cancer Who Have Received No or Only One Prior Line of Endocrine Therapy: A Canadian Healthcare Perspective

Autor: Jinhee Park, M. Thabane, Daniel Stellato, David Chandiwana, Thomas E. Delea

Publikováno v: PharmacoEconomics. 39(9)

The MONALEESA-3 trial demonstrated the efficacy and safety of ribociclib plus fulvestrant versus placebo plus fulvestrant for patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2−) advanced breast

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3cbd402127f77fcca7408662f2b9024e
https://pubmed.ncbi.nlm.nih.gov/34105083

Zobrazit plný text záznamu

Progression-free survival/time to progression as a potential surrogate for overall survival in HR+, HER2– metastatic breast cancer

Autor: Johan Baeck, M. Thabane, Janina Barth, Gabriel Tremblay, Anna Forsythe, David Chandiwana

Publikováno v: Breast Cancer : Targets and Therapy

Anna Forsythe,1 David Chandiwana,2 Janina Barth,3 Marroon Thabane,4 Johan Baeck,2 Gabriel Tremblay1 1Purple Squirrel Economics, New York, NY, 2Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA; 3Novartis Pharma GmbH, Nuremberg, Germany; 4No

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fe01fe6844052680eab6e31e682720c6
https://doi.org/10.2147/bctt.s162841

Zobrazit plný text záznamu

Cost-Effectiveness of Everolimus for the Treatment of Advanced Neuroendocrine Tumours of Gastrointestinal or Lung Origin in Canada

Autor: A Chua, Maureen P. Neary, J F Ricci, A. Perrin, M. Thabane

Publikováno v: Current Oncology
Volume 25
Issue 1
Pages 3532-40

Background: In 2016, everolimus was approved by Health Canada for the treatment of unresectable, locally advanced or metastatic, well-differentiated, non-functional, neuroendocrine tumours (NET) of gastrointestinal (GI) or lung origin in adult patien

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d015350dbac620b058bf389026e0a2ba
https://doi.org/10.3747/co.25.3532

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Vyhledávací nástroje:

Upřesnit hledání